/

RCKT

Rocket Pharmaceuticals, Inc.Open

2.32−0.16 −6.64%USD

NasdaqGM · as of Oct 13, 14:51 ET · 15m delay

Open

2.47

Prev close

2.48

Day range

2.262.55

52-week range

2.265.45

Volume

2.59M1.52×

Mkt cap

254.13M

P/E ttm

—

Fwd P/E

-1.78

EPS ttm

-0.1700

Div yield

0.00%

Earnings

—

From 52w high

−57.52%

Price Chart

Yahoo Finance · delayed

RCKTOct 13, 2026O 2.47H 2.55L 2.26C 2.32−0.16 (−6.65%)Vol 2.59M

SMA 503.26
SMA 2003.54

1Y change −32.31% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

RCKT Rocket Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.65%
1 month: −30.90%
3 months: −36.40%
6 months: −36.40%
Year to date: −34.05%
1 year: −33.29%

Valuation & ownership

Market cap: 254.13M
Enterprise value: 13.29M
P/E (ttm): —
Forward P/E: -1.78
PEG ratio: —
Price / book: 0.69
Price / sales (ttm): —
EV / EBITDA: -0.07
EPS (ttm): -0.1700
EPS (forward): -1.30
Beta (5y monthly): 0.50
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 109.77M
Float: 87.62M
Short % of float: 16.80%
Short ratio (days): 8.45
Held by insiders: 3.18%
Held by institutions: 91.79%
Avg volume (3m): 1.70M
50-day average: 3.28
200-day average: 3.54
52-week change: −33.29%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 27.5
vs 50-day SMA: −29.04%
vs 200-day SMA: −34.52%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.67%
Realised vol (20d, ann.): 66.5%
From 52-week high: −57.52%
From 52-week low: +2.43%

ANR

Analyst Consensus

12 analysts

Consensus

Buy

2.14 on a 1 (strong buy) – 5 (sell) scale

Mean target

8.58

+270.59% implied

Low 2.95Median 9.50High 15.00

Recommendation trend

Now7 / 6 / 1
1m ago

DES

About Rocket Pharmaceuticals, Inc.

Yahoo Finance profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Sector: Healthcare
Industry: Biotechnology
Employees: 202
Headquarters

SEAS

Seasonality · RCKT

2015–2026 · monthly returns

Strongest month Jul +13.88%Weakest month Mar −6.65%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-0.9	44.0	-28.5	-2.8	-11.8	11.4	-9.1	19.6	-29.3	-12.0			−34.0%
2025	-14.6	-12.0	-29.4	14.4	-67.1	-2.4	24.5	7.5	-0.6	15.6	-9.3	2.6	−72.1%
2024	-4.1	2.0	-8.1	-20.1	-0.9	1.0	12.4	-22.1	-2.0	-9.9	-13.6	-12.6	−58.1%
2023	11.0	-11.6	-10.8	4.6	16.8	-5.1	-9.2	-13.3	30.9	-11.7	28.9	28.5	+53.1%
2022	-23.8	7.0	-10.9	-35.2	15.3	16.1	5.4	6.3	3.6	16.9	1.2	3.7	−10.4%
2021	0.4	0.9	-20.2	3.3	-7.3	4.2	-19.1	-4.5	-12.6	-0.6	-17.8	-10.6	−60.2%
2020	-10.0	-4.8	-28.4	6.1	27.1	11.3	12.4	8.7	-10.6	22.2	10.8	77.1	+140.9%
2019	-3.0	21.1	0.7	5.8	-12.0	-8.1	-18.8	-10.9	7.4	24.8	21.0	29.4	+53.6%
2018	82.4	-10.8	10.4	-8.1	12.8	1.0	4.5	16.3	3.2	-35.7	1.7	-8.0	+42.0%
2017	-73.8	0.0	25.0	0.0	-15.0	11.8	-51.9	11.7	74.5	41.6	-8.3	13.0	−57.2%
2016	-30.9	-12.9	8.5	32.4	-6.1	-19.1	27.4	-25.1	33.5	-26.2	-8.6	-4.7	−46.2%
2015			-10.0	11.8	-3.5	-16.2	165.1	-5.1	-23.8	15.9	10.1	-5.5	+88.2%

INSD

Insider Activity · RCKT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

291.9K shares

Sells, 6 months

209.7K shares

Net shares

+82.2K

Net change in insider shares

+2.40%

Date	Insider	Transaction	Shares	Value
Sep 10, 2026	Wilson MartinGeneral Counsel	Sale at price 3.40 per share.	75.4K	$256.46K
Aug 17, 2026	Wilson MartinGeneral Counsel	Sale at price 3.38 per share.	631	$2.13K
Aug 17, 2026	Shah Gaurav DChief Executive Officer	Sale at price 3.38 per share.	2.3K	$7.75K
Aug 12, 2026	Wilson MartinGeneral Counsel	Sale at price 3.38 per share.	3.5K	$11.81K
Aug 12, 2026	Shah Gaurav DChief Executive Officer	Sale at price 3.38 per share.	2.8K	$9.59K
Aug 10, 2026	Chaudhuri SarbaniOfficer	Sale at price 3.50 per share.	4.7K	$16.45K
Aug 10, 2026	Stevens Christopher JamesChief Operating Officer	Sale at price 3.50 per share.	36.7K	$128.27K
Aug 2, 2026	Stevens Christopher JamesChief Operating Officer	Stock Award(Grant) at price 0.00 per share.	73.3K	—
Jun 17, 2026	Southwell David PDirector	Stock Award(Grant) at price 0.00 per share.	22.9K	—
Jun 17, 2026	Boess CarstenDirector	Stock Award(Grant) at price 0.00 per share.	22.9K	—
Jun 17, 2026	Dolsten MikaelDirector	Stock Award(Grant) at price 0.00 per share.	22.9K	—
Jun 17, 2026	Wong RoderickDirector and Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 0.00 per share.	27.8K	—
Jun 17, 2026	Malik Fady IbrahamDirector	Stock Award(Grant) at price 0.00 per share.	22.9K	—
Jun 17, 2026	Fong Peter Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	22.9K	—
May 20, 2026	Shah Gaurav DChief Executive Officer	Conversion of Exercise of derivative security at price 1.69 per share.	76.5K	$129.34K
May 20, 2026	Shah Gaurav DChief Executive Officer	Sale at price 3.09 per share.	55.7K	$171.84K
May 18, 2026	Militello JohnOfficer and Treasurer	Sale at price 3.01 per share.	384	$1.16K
May 18, 2026	Wilson MartinGeneral Counsel	Sale at price 3.01 per share.	662	$2.00K
May 18, 2026	Shah Gaurav DChief Executive Officer	Sale at price 3.01 per share.	2.4K	$7.26K
May 12, 2026	Militello JohnOfficer and Treasurer	Sale at price 3.61 per share.	855	$3.08K

13F

Investors Holding RCKT

latest 13F filings of 29 followed managers

Investors holding RCKT
Investor	Value	Of portfolio	Shares	Change	Quarter
Maverick Capital · Lee Ainslie	$13.4M	0.12%	3.92M	+10.0%	Q2 2026
Renaissance Technologies	$2.7M	0.00%	792.97K	+24%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

RCKT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

RCKT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Rocket Pharmaceuticals, Inc.

Seasonality · RCKT

Insider Activity · RCKT

Congress Trades · RCKT

Investors Holding RCKT

Investors Holding RCKT

Congress Trades · RCKT

Insider Activity · RCKT

Seasonality · RCKT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Rocket Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News